Related Experiment Videos
Purine receptors: GPCR structure and agonist design
Kenneth A Jacobson1, Soo-Kyung Kim, Stefano Costanzi
1Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Molecular Interventions
|December 24, 2004
Summary
Researchers studied drug-receptor interactions for adenosine receptors (ARs) and P2Y nucleotide receptors. They engineered receptors and ligands for precise control, enabling potential gene therapy applications.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- Drug-receptor interactions are crucial for therapeutic development.
- Adenosine receptors (ARs) and P2Y nucleotide receptors are key targets.
- Understanding binding sites enables rational drug design.
Purpose of the Study:
- To investigate drug-receptor interactions using an integrated structural approach.
- To enable rational design of novel agonists and antagonists with improved selectivity.
- To explore receptor engineering for targeted activation via synthetic ligands.
Main Methods:
- Site-directed mutagenesis to probe receptor structure.
- Molecular modeling to predict binding site locations.
- Ligand structure modification to alter agonist/antagonist properties.
Main Results:
- Achieved increased receptor subtype selectivity.
- Successfully converted agonists into partial agonists and antagonists.
- Demonstrated orthogonal receptor activation using engineered receptors (neoceptors) and tailored ligands (neoligands) for A3 and A2A ARs.
Conclusions:
- An integrated approach effectively elucidates drug-receptor interactions.
- Receptor engineering offers a novel strategy for precise pharmacological control.
- This method holds promise for future gene therapy applications.